MA41677A - Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8 - Google Patents
Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8Info
- Publication number
- MA41677A MA41677A MA041677A MA41677A MA41677A MA 41677 A MA41677 A MA 41677A MA 041677 A MA041677 A MA 041677A MA 41677 A MA41677 A MA 41677A MA 41677 A MA41677 A MA 41677A
- Authority
- MA
- Morocco
- Prior art keywords
- alpha
- compositions
- hdac8 inhibitors
- cinnamide compounds
- cinnamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562132895P | 2015-03-13 | 2015-03-13 | |
US201562184335P | 2015-06-25 | 2015-06-25 | |
US201562270371P | 2015-12-21 | 2015-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41677A true MA41677A (fr) | 2021-06-02 |
Family
ID=55590170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041677A MA41677A (fr) | 2015-03-13 | 2016-03-11 | Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8 |
Country Status (21)
Country | Link |
---|---|
US (6) | US9745253B2 (fr) |
EP (2) | EP3932914A1 (fr) |
JP (1) | JP2018531213A (fr) |
KR (1) | KR20170124602A (fr) |
CN (1) | CN107531660A (fr) |
AU (1) | AU2016233568A1 (fr) |
BR (1) | BR112017019453A2 (fr) |
CA (1) | CA2979391C (fr) |
CO (1) | CO2017009298A2 (fr) |
CR (1) | CR20170420A (fr) |
EA (1) | EA201792028A1 (fr) |
EC (1) | ECSP17064695A (fr) |
HK (1) | HK1249104A1 (fr) |
IL (1) | IL254383A0 (fr) |
MA (1) | MA41677A (fr) |
MX (1) | MX2017011778A (fr) |
PE (1) | PE20171517A1 (fr) |
PH (1) | PH12017501669A1 (fr) |
SG (1) | SG11201707418WA (fr) |
TW (1) | TW201639811A (fr) |
WO (1) | WO2016149099A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20170420A (es) | 2015-03-13 | 2017-10-03 | Forma Therapeutics Inc | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 |
US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
WO2017040963A1 (fr) | 2015-09-03 | 2017-03-09 | Forma Therapeutics, Inc. | Inhibiteurs de hdac8 bicyclique [6,6] fusionnée |
TWI659949B (zh) | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | 組蛋白去乙醯酶6抑制劑及其用途 |
TW201821105A (zh) | 2016-10-20 | 2018-06-16 | 美商弗瑪治療公司 | 使用hdac11抑制劑之方法 |
CN107056631A (zh) * | 2017-04-14 | 2017-08-18 | 六盘水师范学院 | 一种基于Heck反应的2‑烯基苯胺类化合物制备方法 |
US11230524B2 (en) * | 2017-08-17 | 2022-01-25 | Standard Llc | Myocyte enhancer factor 2 (MEF2) modulators |
EP3784654A4 (fr) * | 2018-04-20 | 2021-10-13 | Valo Early Discovery, Inc. | Isoindolines utilisées comme inhibiteurs de hdac |
US11535607B2 (en) | 2018-04-20 | 2022-12-27 | Valo Health, Inc. | Isoindolines as HDAC inhibitors |
KR102055369B1 (ko) * | 2018-08-09 | 2019-12-12 | 충북대학교 산학협력단 | 신규한 3/4-((치환된 벤즈아미도페녹시)메틸)-n-히드록시 벤즈아미드/프로펜아미드 화합물 및 이의 용도 |
ES2963508T3 (es) * | 2018-12-06 | 2024-03-27 | Novartis Ag | Derivados de 5-hidroxi-7-oxabiciclo[2.2.1]heptano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular |
CN113493407A (zh) * | 2020-04-03 | 2021-10-12 | 中国医学科学院药物研究所 | 一种吡啶类化合物及其制法和药物用途 |
CN111728961B (zh) * | 2020-08-05 | 2021-06-15 | 牡丹江医学院 | 一种用于治疗老年痴呆的药物组合物及其用途 |
CN114605304A (zh) * | 2020-12-04 | 2022-06-10 | 杭州中美华东制药有限公司 | 一种(±)-2-(4-(1-氧代异吲哚-2-基)苯基)丁酸乙酯的合成方法 |
CN113192633B (zh) * | 2021-05-24 | 2022-05-31 | 山西大学 | 基于注意力机制的胃癌细粒度分类方法 |
KR20230141506A (ko) | 2022-03-31 | 2023-10-10 | 재단법인 대구경북첨단의료산업진흥재단 | 3,4-다이하이드로퀴녹살린-2-카복사미드 유도체 화합물 및 이를 포함하는 암 질환 예방 또는 치료용 약학적 조성물 |
CN115417877A (zh) * | 2022-09-20 | 2022-12-02 | 杭州师范大学 | 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用 |
Family Cites Families (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4834699B1 (fr) | 1968-07-03 | 1973-10-23 | ||
GB8320702D0 (en) | 1983-08-01 | 1983-09-01 | Wellcome Found | Chemotherapeutic agents |
GB8531839D0 (en) | 1985-12-30 | 1986-02-05 | Wellcome Found | Aryl derivatives |
US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
GB8820185D0 (en) | 1988-08-25 | 1988-09-28 | Wellcome Found | New medical use |
US5466704A (en) | 1991-02-26 | 1995-11-14 | E. R. Squibb & Sons, Inc. | N-substituted imidazole and benzimidazole derivatives useful as angiotenson II antagonists |
US5534654A (en) | 1991-12-10 | 1996-07-09 | Shionogi & Co., Ltd. | Aromatic-sulfonamide-type hydroxamic acid derivative |
US5234923A (en) | 1991-12-16 | 1993-08-10 | E. R. Squibb & Sons, Inc. | Substitute indole and benzimidazole derivatives |
US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
EP0664792B1 (fr) | 1992-10-14 | 2000-01-05 | Merck & Co. Inc. | Antagonistes des recepteurs du fibrinogene |
JPH06130434A (ja) | 1992-10-19 | 1994-05-13 | Hoechst Japan Ltd | 有機非線形光学材料 |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
DE4238260A1 (de) | 1992-11-12 | 1994-05-19 | Basf Ag | Substituierte ortho-Ethenylphenylessigsäurederivate |
CN1073571A (zh) | 1992-11-28 | 1993-06-30 | 黄尊景 | 防止坡面被冲刷的施工法 |
WO1994012181A1 (fr) | 1992-12-01 | 1994-06-09 | Merck & Co., Inc. | Antagonistes des recepteurs du fibrinogene |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
JP3203108B2 (ja) | 1993-08-26 | 2001-08-27 | 協和メデックス株式会社 | グルコース−6−リン酸デヒドロゲナーゼの安定化方法 |
WO1995013264A1 (fr) | 1993-11-08 | 1995-05-18 | Terumo Kabushiki Kaisha | Derive d'acide hydroxamique et preparation medicamenteuse contenant ledit derive |
US6872542B1 (en) | 1993-11-18 | 2005-03-29 | Siga Pharmaceuticals, Inc. | Treatment or prophylaxis of diseases caused by pilus-forming bacteria |
US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
KR100232341B1 (ko) | 1994-10-13 | 2000-07-01 | 디. 제이. 우드 | 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물 |
MX9702734A (es) | 1994-10-13 | 1997-06-28 | Pfizer | Benzopirano y compuestos benzocondensados, su preparacion y su uso como antagonistas de leucotrieno b4 (ltb4). |
US5851233A (en) | 1994-10-20 | 1998-12-22 | Novo Nordisk A/S | Bleaching process comprising use of a phenol oxidizing enzyme, a hydrogen peroxide source and an enhancing agent |
EP0717143A1 (fr) | 1994-12-16 | 1996-06-19 | Lignozym GmbH | Système à plusieurs composants pour modifier, dégrader ou blanchir la lignine, des matériaux contenant de la lignine ou des produits similaires de même que leur procédé d'utilisation |
ATE219765T1 (de) | 1995-04-10 | 2002-07-15 | Fujisawa Pharmaceutical Co | Indolderivate als cgmp-pde inhibitoren |
JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
IL123421A0 (en) | 1995-09-18 | 1998-09-24 | Basf Ag | Phenylacetic acids their preparation and compositions comprising them |
US5795890A (en) | 1995-09-27 | 1998-08-18 | Ono Pharmaceutical Co., Ltd. | Sulfonamide derivatives |
MY127641A (en) | 1995-10-12 | 2006-12-29 | Essential Therapeutics Inc | Cephalosporin antibiotics |
JPH09268125A (ja) | 1996-04-02 | 1997-10-14 | Terumo Corp | 腎炎治療薬 |
US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
EP0845026A1 (fr) | 1996-06-19 | 1998-06-03 | CALL, Hans-Peter Dr. | Systeme multicomposant destine a etre utilise avec des substances detersives |
WO1997049684A1 (fr) | 1996-06-24 | 1997-12-31 | Novo Nordisk A/S | Reactif se fixant au facteur vii |
AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
JP2001510168A (ja) | 1997-07-18 | 2001-07-31 | ノボ ノルディスク アクティーゼルスカブ | FVIIa媒介性細胞内シグナル伝達経路に関連する反対条件の処理のためのFVIIa又はFVIIaiの使用 |
CA2307613A1 (fr) | 1997-10-22 | 1999-04-29 | Eisai Co., Ltd. | Agonistes de l'acide retinoique, agents preventifs et therapeutiques des nephrites |
US20020128256A1 (en) | 1997-11-20 | 2002-09-12 | Carlo Brugnara | Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation |
IL128731A0 (en) | 1998-03-12 | 2000-01-31 | Pfizer Prod Inc | Method of preventing allograft rejection |
EP0963755A3 (fr) | 1998-04-16 | 2001-03-14 | Pfizer Products Inc. | Utilisation des benzopyranes pour la prévention de rejets de graiffes |
JP2002517383A (ja) | 1998-06-03 | 2002-06-18 | ジーピーアイ ニル ホールディングス インコーポレイテッド | 神経学上の障害および毛髪損失を治療するために使用されるaza−複素環式化合物 |
US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
CA2367895A1 (fr) | 1999-03-17 | 2000-09-21 | Signal Pharmaceuticals, Inc. | Composes et techniques de modulation des recepteurs des oestrogenes |
US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
RU2312860C2 (ru) | 1999-04-15 | 2007-12-20 | Бристол-Маерс Сквибб Компани | Циклические ингибиторы протеинтирозинкиназ |
DE60020556T2 (de) | 1999-05-12 | 2005-10-27 | Neurosearch A/S | Ionenkanal modulierende mittel |
WO2001021592A1 (fr) | 1999-09-20 | 2001-03-29 | Nippon Soda Co., Ltd. | Procede de preparation de 4(5)-amino-5(4)-carboxamidoimidazoles et de leurs produits intermediaires |
DK1233958T3 (da) | 1999-11-23 | 2011-10-17 | Methylgene Inc | Hæmmere af histondeacetylase |
US20020019395A1 (en) | 2000-02-01 | 2002-02-14 | Bing-Yan Zhu | Indalone and benzimidazolone inhibitors of factor Xa |
WO2001064681A2 (fr) | 2000-02-28 | 2001-09-07 | Sugen, Inc. | Composes de 3-(pyrolyllactone)-2-indolinone comme inhibiteurs des kinases |
EP1272483A2 (fr) | 2000-03-24 | 2003-01-08 | Millenium Pharmaceuticals, Inc. | INHIBITEURS D'OXINIDOLE DU FACTEUR Xa |
AU2001253206A1 (en) | 2000-04-05 | 2001-10-23 | Tularik, Inc. | Ns5b hcv polymerase inhibitors |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
DE60138658D1 (de) | 2000-09-29 | 2009-06-18 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria |
WO2002030879A2 (fr) | 2000-09-29 | 2002-04-18 | Prolifix Limited | Composes d'acide carbamique comprenant une liaison sulfonamide en tant qu'inhibiteurs de hdac |
US20030152557A1 (en) | 2001-01-12 | 2003-08-14 | Besterman Jeffrey M. | Methods for inhibiting histone deacetylase-4 |
US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
US8026280B2 (en) | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
CA2448076A1 (fr) | 2001-05-24 | 2002-11-28 | Masahiko Hayakawa | Derives de 3-quinoleine-2-(1h)-ylideneindoline-2-one |
WO2003000251A1 (fr) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Nouvelles indolinones et leurs applications |
ES2280597T3 (es) | 2001-11-06 | 2007-09-16 | Novartis Ag | Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de histona desacetilasa. |
ES2289171T3 (es) | 2001-12-21 | 2008-02-01 | Astrazeneca Ab | Uso de derivados de oxindol en el tratamiento de trastornos relacionados con la demencia, de la enfermedad de alzheimer y afecciones asociadas con glucogeno sintasa quinasa-3. |
US20030199558A1 (en) | 2001-12-28 | 2003-10-23 | Integriderm, Inc. | Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners |
ES2309313T3 (es) | 2002-04-03 | 2008-12-16 | Topotarget Uk Limited | Compuestos del acido carbamico que comprenden un acoplamiento de piperacina como hdac inhibidores. |
US7615640B2 (en) | 2002-07-29 | 2009-11-10 | Mitsubishi PaperMillsLtd. | Organic dye, photoelectric conversion material, semiconductor electrode and photoelectric conversion device |
EP1527345A2 (fr) | 2002-07-29 | 2005-05-04 | Axxima Pharmaceuticals AG | Milieu et methode d'enrichissement, de purification ou d'appauvrissement de proteines de liaison a l'atp a partir d'un reservoir de proteines |
CA2493908A1 (fr) | 2002-08-08 | 2004-02-19 | Smithkline Beecham Corporation | Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
US7626031B2 (en) | 2002-11-15 | 2009-12-01 | Symphony Evolution, Inc. | Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use |
GB0226855D0 (en) | 2002-11-18 | 2002-12-24 | Queen Mary & Westfield College | Histone deacetylase inhibitors |
DE60312548T2 (de) | 2002-11-18 | 2007-12-13 | Galderma Research & Development, S.N.C. | Neue liganden, die antagonisten der rar-rezeptoren sind, herstellungsverfahren für diese liganden und verwendung dieser liganden in der humanmedizin und in der kosmetik |
TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
US7084189B2 (en) | 2003-02-20 | 2006-08-01 | Xerox Corporation | Phase change inks with isocyanate-derived antioxidants and UV stabilizers |
JP2006520796A (ja) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
SE0301699D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
WO2004113336A1 (fr) | 2003-06-16 | 2004-12-29 | Chroma Therapeutics Limited | Derives de carboline et de betacarboline inhibiteurs de l'enzyme hdac |
WO2005013958A1 (fr) | 2003-08-07 | 2005-02-17 | Novartis Ag | Inhibiteurs d'histone deacetylase utilises comme immunosuppresseurs |
EP1664006A2 (fr) | 2003-09-06 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs a cassette de liaison a l'atp |
US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
WO2005025557A1 (fr) | 2003-09-16 | 2005-03-24 | Monash University | Agent traitant les etats associes a l'activation du plasminogene et a la metalloproteinase matricielle, et ses procedes d'utilisation |
JP5042626B2 (ja) | 2003-09-22 | 2012-10-03 | エス*バイオ プライベート リミティッド | ベンズイミダゾール誘導体:製造及び医薬適用 |
EP1682538A4 (fr) | 2003-10-27 | 2009-05-27 | S Bio Pte Ltd | Hydroxamates lies au biaryle: preparation et applications pharmaceutiques |
JP2005145928A (ja) | 2003-11-19 | 2005-06-09 | Yamanouchi Pharmaceut Co Ltd | 3−キノリン−2(1h)−イリデンインドリン−2−オン誘導体を有効成分とする医薬組成物 |
US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
WO2005065681A1 (fr) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Derives de n-hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide et composes associes en tant qu'inhibiteurs d'histone deacetylase pour le traitement du cancer |
US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
US20080234271A1 (en) | 2004-04-28 | 2008-09-25 | Icos Corporation | Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them |
DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
US20050261327A1 (en) | 2004-05-20 | 2005-11-24 | Bock Mark G | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation |
MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
WO2006020004A2 (fr) | 2004-07-19 | 2006-02-23 | Merck & Co., Inc. | Inhibiteurs de l'histone deacetylase |
CA2576667A1 (fr) | 2004-08-09 | 2006-02-16 | Astellas Pharma Inc. | Composes d'hydroxyamide presentant une activite en tant qu'inhibiteurs d'histone desacetylase (hdac) |
EP1781288A2 (fr) | 2004-08-19 | 2007-05-09 | Vertex Pharmaceuticals Incorporated | Modulateurs des recepteurs muscariniques |
WO2006029575A1 (fr) | 2004-09-17 | 2006-03-23 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux acides $g(a)-alkyloxy propioniques, leurs procedes de preparation, compositions pharmaceutiques les contenant et leurs utilisations |
US8242175B2 (en) | 2004-10-01 | 2012-08-14 | Dac S.R.L. | Class of histone deacetylase inhibitors |
FR2878247B1 (fr) | 2004-11-19 | 2008-10-03 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
CA2589501A1 (fr) | 2004-12-17 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Indolinones et leur emploi en tant qu'agents antiproliferants |
EP2298295B1 (fr) | 2005-01-31 | 2013-08-28 | Cephalon, Inc. | Inhibiteurs du facteur de nécrose tumorale |
WO2006088949A1 (fr) | 2005-02-14 | 2006-08-24 | Miikana Therapeutics, Inc. | Composes heterocycliques fusionnes utiles comme inhibiteurs de l'histone deacetylase |
WO2006101456A1 (fr) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Composes d'hydraxamate bicycliques contenant des heterocycles utiles en tant qu'inhibiteurs de l'histone desacetylase (hdac) |
CA2601983A1 (fr) | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Heterocycles substitues et leur utilisation en tant qu'inhibiteurs de la chk1, de la pdk1 et de la pak |
NZ563236A (en) | 2005-05-13 | 2010-12-24 | Topotarget Uk Ltd | Pharmaceutical formulations of N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, aka PXD-101, and arginine |
GB0510204D0 (en) * | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
KR101333861B1 (ko) | 2005-05-24 | 2013-11-28 | 메르크 세로노 에스. 에이. | Crth2 조정자로서 삼환계 스피로 유도체 |
US7399786B2 (en) | 2005-06-30 | 2008-07-15 | Bexel Pharmaceuticals, Inc. | Derivatives of amino acids for treatment of obesity and related disorders |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
JP2007056213A (ja) | 2005-08-26 | 2007-03-08 | Fujifilm Corp | 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材 |
WO2007030455A2 (fr) | 2005-09-07 | 2007-03-15 | Novartis Ag | Mutations et polymorphismes de hdac10 |
TW200745066A (en) | 2005-09-16 | 2007-12-16 | Torrent Pharmaceuticals Ltd | Novel PTP1B inhibitors |
AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
EP1973543A2 (fr) | 2005-12-22 | 2008-10-01 | Vertex Pharmaceuticals Incorporated | Modulateurs de recepteurs muscariniques |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
EP2402334B1 (fr) | 2006-02-02 | 2016-06-29 | Millennium Pharmaceuticals, Inc. | Inhibiteurs d'enzymes à activation E1 |
US8222423B2 (en) | 2006-02-14 | 2012-07-17 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
FI20065162A0 (fi) | 2006-03-13 | 2006-03-13 | Wallac Oy | Terminoivia DNA polymeraasisubstraatteja |
EP2019094A4 (fr) | 2006-05-19 | 2011-01-05 | Eisai R&D Man Co Ltd | Dérivé de cinnamide de type hétérocyclique |
US7482475B2 (en) | 2006-08-11 | 2009-01-27 | Allergan, Inc. | Therapeutic lactams |
EP2061758A4 (fr) | 2006-09-11 | 2011-11-30 | Curis Inc | 2-indolinone substituée en tant qu'inhibiteur de la ptk contenant une fraction se liant au zinc |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
US7820711B2 (en) | 2006-11-14 | 2010-10-26 | Pharmacyclics Inc. | Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders |
US8093220B2 (en) | 2006-12-04 | 2012-01-10 | Novartis Ag | Combination of an HDAC inhibitor and an antimetabolite |
JP2010513223A (ja) | 2006-12-15 | 2010-04-30 | アステラス製薬株式会社 | N−ヒドロキシアクリルアミド化合物 |
US8796330B2 (en) | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
EP2109607A1 (fr) | 2006-12-21 | 2009-10-21 | Schering Corporation | Dérivé de pyrrolo [3, 2-a]pyridine pour inhiber l'activité de la kinésine ksp |
WO2008089125A2 (fr) | 2007-01-15 | 2008-07-24 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases | Composés antiviraux et leurs procédés d'utilisation |
WO2008087514A2 (fr) | 2007-01-17 | 2008-07-24 | Orchid Research Laboratories Limited | Inhibiteurs d'hdac |
ITRM20070038A1 (it) | 2007-01-26 | 2008-07-27 | Uni Degli Studi Di Roma La Sapienza | Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico |
US7985763B2 (en) | 2007-04-10 | 2011-07-26 | National Health Research Institutes | Hepatitis C virus inhibitors |
BRPI0811227A2 (pt) | 2007-05-24 | 2014-10-29 | Basf Se | Composotos de amino-tiouréia substituídos, composição, métodos para combater ou controlar insetos, aracnídeos ou nematóides, para proteger plantas em crescimento do ataque ou infestação por insetos, aracnídeos ou nematóides, para proteger sementes de insetos do solo e das raízes das mudas e ramos de insetos do solo e folhas e para tratar, controlar, prevenir ou proteger animais contra infestação ou infecção por parasitas, semente, uso de compostos, e, processo para a preparação de uma composição. |
EP2181108A2 (fr) | 2007-06-12 | 2010-05-05 | Boehringer Ingelheim International GmbH | Dérivés de 3-héterocyclylidene-2-indolone comme inhibiteurs des kinases du cycle cellulaire contre la proliferation cellulaire exzessive ou anomale |
JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP5105108B2 (ja) | 2007-09-26 | 2012-12-19 | Jsr株式会社 | 液晶配向剤、液晶配向膜および液晶表示素子 |
US8476255B2 (en) | 2007-10-10 | 2013-07-02 | Orchid Chemicals & Pharmaceuticals Limited | Histone deacetylase inhibitors |
EP2060565A1 (fr) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Nouveaux composés bifonctionnels inhibiteurs de protéine kinases et d'histone deacetylases |
ES2403284T3 (es) | 2008-01-09 | 2013-05-17 | Array Biopharma, Inc. | Pirimidil ciclopentanos como inhibidores de la proteína quinasa AKT |
EP2257546B1 (fr) | 2008-02-21 | 2012-08-15 | Merck Sharp & Dohme Corp. | Agonistes fonctionnellement sélectifs du récepteur adrénergique alpha2c |
EP2260020B1 (fr) * | 2008-03-26 | 2014-07-23 | Novartis AG | Inhibiteurs de désacétylases b à base d'hydroxamate |
ES2336746B1 (es) | 2008-04-10 | 2011-01-25 | Universitat De Girona | Catalizadores de manganeso y su uso para la epoxidacion selectiva de olefinas. |
US8198284B2 (en) | 2008-04-30 | 2012-06-12 | National Health Research Institutes | Treatment of neurodegenerative disorders with thiourea compounds |
WO2009152210A2 (fr) | 2008-06-12 | 2009-12-17 | National Health Research Institutes | Composés de coumarine et leur utilisation pour traiter un cancer |
US20090312406A1 (en) | 2008-06-12 | 2009-12-17 | Hsing-Pang Hsieh | Coumarin compounds and their use for treating viral infection |
US20110224242A1 (en) | 2008-07-23 | 2011-09-15 | Bioalliance Pharma | Styrlyquinolines, their process of preparation and their therapeutic uses |
EP2149557A1 (fr) | 2008-07-23 | 2010-02-03 | BioAlliance Pharma | Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques |
KR20110046503A (ko) | 2008-07-24 | 2011-05-04 | 지멘스 메디컬 솔루션즈 유에스에이, 인크. | Ad 병인을 확인하기에 유용한 영상화제 |
WO2010017827A1 (fr) | 2008-08-14 | 2010-02-18 | European Molecular Biology Laboratory | Dérivés 1-sulfonyl-2,3-dihydro-indoles substitués en position 6 destinés au traitement de maladies prolifératives |
JP2010077096A (ja) | 2008-09-29 | 2010-04-08 | Fujifilm Corp | 化合物、液晶性組成物、膜、及び位相差板 |
AU2009304598B2 (en) | 2008-10-17 | 2015-01-29 | Akaal Pharma Pty Ltd | S1P receptors modulators and their use thereof |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
US20110237633A1 (en) | 2008-12-11 | 2011-09-29 | Bijoy Panicker | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
WO2010077310A2 (fr) | 2008-12-17 | 2010-07-08 | The Regents Of The University Of California | Dérivés amides de l'acide éthacrynique |
AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
US7897602B2 (en) | 2009-01-12 | 2011-03-01 | Development Center For Biotechnology | Indolinone compounds as kinase inhibitors |
WO2010086311A1 (fr) | 2009-01-28 | 2010-08-05 | Bayer Cropscience Ag | Dérivés de n-cycloalkyl-n-bicyclométhylène-carboxamide fongicides |
PE20120603A1 (es) | 2009-02-10 | 2012-06-14 | Astrazeneca Ab | Derivados de triazolo[4,3-b]piridazina y sus usos para el cancer de prostata |
GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
US8927576B2 (en) | 2009-04-06 | 2015-01-06 | PTC Therpeutics, Inc. | HCV inhibitor and therapeutic agent combinations |
TW201039827A (en) | 2009-04-15 | 2010-11-16 | Daiichi Sankyo Co Ltd | Indoline compound |
WO2011021209A1 (fr) | 2009-07-07 | 2011-02-24 | Portsmouth Technologies Llc | Inhibiteurs de lhistone désacétylase |
KR101118587B1 (ko) | 2009-08-17 | 2012-06-12 | 포항공과대학교 산학협력단 | 감응성 고분자 캡슐 및 그 제조방법 |
US20110053925A1 (en) * | 2009-08-28 | 2011-03-03 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
NZ601176A (en) | 2009-12-14 | 2014-03-28 | Univ Basel | Mannose derivatives as antagonists of bacterial adhesion |
US20130040998A1 (en) | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
US9260382B2 (en) | 2010-02-16 | 2016-02-16 | Uwm Research Foundation | Methods of reducing virulence in bacteria |
WO2011106650A2 (fr) | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nouveaux antagonistes de p53-mdm2/p53-mdm4 pour traiter une maladie de prolifération |
TWI429628B (zh) | 2010-03-29 | 2014-03-11 | Univ Taipei Medical | 吲哚基或吲哚啉基羥肟酸化合物 |
WO2011145035A1 (fr) | 2010-05-17 | 2011-11-24 | Indian Incozen Therapeutics Pvt. Ltd. | Nouveau composés de 3,5-disubstitués-3h-imidazo[4,5-b]pyridine et 3,5- disubstitués -3h-[1,2,3]triazolo[4,5-b] pyridine utilisés comme modulateurs des protéines kinases |
ES2526124T3 (es) | 2010-06-16 | 2015-01-07 | Cymabay Therapeutics, Inc. | Agonistas del receptor GPR120 y sus usos |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
WO2012016184A2 (fr) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Procédés et compositions pour la délivrance d'agents actifs |
EP2606031B1 (fr) | 2010-08-20 | 2017-09-27 | Amira Pharmaceuticals, Inc. | Inhibiteurs de l'autotaxine et leurs utilisations |
CA2818050A1 (fr) | 2010-11-26 | 2012-05-31 | Lupin Limited | Modulateurs de gpr119 bicycliques |
TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
US9708299B2 (en) | 2011-01-03 | 2017-07-18 | Genentech, Inc. | Hedgehog antagonists having zinc binding moieties |
ES2734878T3 (es) | 2011-02-01 | 2019-12-12 | Univ Illinois | Derivados de N-hidroxibenzamida como inhibidores de HDAC y métodos terapéuticos que utilizan los mismos |
US20120225846A1 (en) | 2011-03-02 | 2012-09-06 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
WO2012117421A1 (fr) | 2011-03-02 | 2012-09-07 | Orchid Research Laboratories Ltd | Inhibiteurs de l'histone désacétylase |
WO2012117021A2 (fr) | 2011-03-03 | 2012-09-07 | Syngenta Participations Ag | Nouveaux éthers d'oxime microbiocides |
WO2012164074A1 (fr) | 2011-06-03 | 2012-12-06 | University Of Basel | Dérivés de mannose phosphate en tant qu'antagonistes de l'adhésion bactérienne |
WO2013024427A1 (fr) | 2011-08-16 | 2013-02-21 | Glenmark Pharmaceuticals S.A. | Nouveaux dérivés d'urée en tant qu'inhibiteurs de kinase tec et leurs utilisations |
WO2013040527A1 (fr) | 2011-09-16 | 2013-03-21 | Microbiotix, Inc. | Composés antimicrobiens |
EP2763531A4 (fr) | 2011-10-03 | 2015-11-18 | Univ Columbia | Nouvelles molécules qui inhibent sélectivement l'histone-déacétylase 6 par rapport à l'histone-déacétylase 1 |
WO2013092460A1 (fr) | 2011-12-20 | 2013-06-27 | Syngenta Participations Ag | Microbicides bisoximes cycliques |
WO2013101600A1 (fr) * | 2011-12-29 | 2013-07-04 | Pharmacyclics, Inc. | Hydroxyamides d'acide cinnamique en tant qu'inhibiteurs d'histone désacétylase 8 |
AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
JP5885140B2 (ja) | 2012-02-28 | 2016-03-15 | 国立大学法人 岡山大学 | Rxrパーシャルアゴニスト |
WO2013134079A1 (fr) | 2012-03-05 | 2013-09-12 | Amgen Inc. | Composés d'oxazolidinone et leurs dérivés |
CN103373997B (zh) | 2012-04-21 | 2015-07-15 | 通化济达医药有限公司 | 含有锌结合基的吡啶并萘啶类HDAC和mTOR抑制剂 |
CN103374021B (zh) | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
US9458174B2 (en) | 2012-05-23 | 2016-10-04 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof |
CN104428293B (zh) | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
CN102701958B (zh) | 2012-06-29 | 2014-12-31 | 常州大学 | 新型抗菌剂酰基苯氧乙酸、酰基肉桂酸及其制备方法 |
CN103524372B (zh) | 2012-07-03 | 2015-06-10 | 南京圣和药业股份有限公司 | 一种组蛋白去乙酰化酶抑制剂 |
CA2883574A1 (fr) | 2012-09-05 | 2014-03-13 | Bayer Cropscience Ag | Utilisation de 2-amidobenzimidazoles, de 2-amidobenzoxazoles et de 2-amidobenzothiazoles substitues ou de leurs sels comme principes actifs contre le stress abiotique des plantes |
WO2014046544A1 (fr) | 2012-09-21 | 2014-03-27 | Aapa B.V. | 3-hétéroaryloxy-3-(hétéro)aryl-propylamines substituées comme modulateurs de transporteur de la sérotonine et du récepteur ht2c de la sérotonine |
CN105008323B (zh) | 2012-10-31 | 2018-11-06 | 密歇根大学董事会 | 纤溶酶原激活物抑制因子-1抑制剂和其使用方法 |
CN103755595A (zh) | 2012-12-25 | 2014-04-30 | 中南大学 | 异羟肟酸类衍生物及其应用 |
KR101988930B1 (ko) | 2012-12-31 | 2019-06-13 | 동우 화인켐 주식회사 | 감광성 수지 조성물 및 이로부터 제조되는 절연막 |
WO2014124651A1 (fr) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Dérivés de pyrrolidine-2-acide carboxylique utilisés en tant qu'antagonistes de iglur |
ES2635016T3 (es) | 2013-03-01 | 2017-10-02 | Fundación Para La Investigación Médica Aplicada | Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas |
US9227962B2 (en) | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
JP2016512219A (ja) | 2013-03-15 | 2016-04-25 | シンジェンタ パーティシペーションズ アーゲー | 殺菌活性のあるイミダゾピリジン誘導体 |
US9193736B2 (en) | 2013-06-11 | 2015-11-24 | Janssen Pharmaceutica, Nv | PDE 10a inhibitors for the treatment of type II diabetes |
JP2016530273A (ja) * | 2013-08-20 | 2016-09-29 | シティ・オブ・ホープCity of Hope | 癌を治療するためのhdac8阻害剤 |
JP6726658B2 (ja) | 2014-04-11 | 2020-07-22 | イェン、ユンYEN,Yun | ヒストン脱アセチル化酵素阻害剤 |
CN103936752A (zh) | 2014-05-05 | 2014-07-23 | 潍坊博创国际生物医药研究院 | 靛红类组蛋白去乙酰化酶抑制剂及其制备方法和应用 |
MX2020003488A (es) | 2015-02-02 | 2022-05-24 | Forma Therapeutics Inc | Acidos 3-alquil-4-amido-biciclico [4,5,0] hidroxamicos como inhibidores de histona desacetilasas (hdac). |
AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
CR20170420A (es) | 2015-03-13 | 2017-10-03 | Forma Therapeutics Inc | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 |
US9637453B2 (en) | 2015-04-17 | 2017-05-02 | Forma Therapeutics, Inc. | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors |
WO2017040963A1 (fr) | 2015-09-03 | 2017-03-09 | Forma Therapeutics, Inc. | Inhibiteurs de hdac8 bicyclique [6,6] fusionnée |
EP3472131B1 (fr) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | Acides hydroxamiques de 2-spiro-indan-5-yl ou de 2-spiro-indan-6-yl utilisés en tant qu'inhibiteurs de hdac |
-
2016
- 2016-03-11 CR CR20170420A patent/CR20170420A/es unknown
- 2016-03-11 EA EA201792028A patent/EA201792028A1/ru unknown
- 2016-03-11 MX MX2017011778A patent/MX2017011778A/es unknown
- 2016-03-11 KR KR1020177029485A patent/KR20170124602A/ko not_active Application Discontinuation
- 2016-03-11 CA CA2979391A patent/CA2979391C/fr active Active
- 2016-03-11 EP EP21169630.7A patent/EP3932914A1/fr active Pending
- 2016-03-11 TW TW105107607A patent/TW201639811A/zh unknown
- 2016-03-11 MA MA041677A patent/MA41677A/fr unknown
- 2016-03-11 PE PE2017001532A patent/PE20171517A1/es not_active Application Discontinuation
- 2016-03-11 JP JP2017548165A patent/JP2018531213A/ja active Pending
- 2016-03-11 EP EP16711758.9A patent/EP3268358A1/fr not_active Withdrawn
- 2016-03-11 CN CN201680025457.5A patent/CN107531660A/zh active Pending
- 2016-03-11 SG SG11201707418WA patent/SG11201707418WA/en unknown
- 2016-03-11 US US15/067,605 patent/US9745253B2/en active Active
- 2016-03-11 AU AU2016233568A patent/AU2016233568A1/en not_active Abandoned
- 2016-03-11 WO PCT/US2016/022029 patent/WO2016149099A1/fr active Application Filing
- 2016-03-11 BR BR112017019453A patent/BR112017019453A2/pt not_active Application Discontinuation
-
2017
- 2017-08-28 US US15/688,732 patent/US20180044282A1/en not_active Abandoned
- 2017-09-07 IL IL254383A patent/IL254383A0/en unknown
- 2017-09-13 PH PH12017501669A patent/PH12017501669A1/en unknown
- 2017-09-14 CO CONC2017/0009298A patent/CO2017009298A2/es unknown
- 2017-10-02 EC ECIEPI201764695A patent/ECSP17064695A/es unknown
-
2018
- 2018-03-19 US US15/925,559 patent/US10266487B2/en active Active
- 2018-07-10 HK HK18108932.4A patent/HK1249104A1/zh unknown
-
2019
- 2019-04-18 US US16/387,937 patent/US10508077B2/en active Active
- 2019-11-20 US US16/689,252 patent/US10988441B2/en active Active
-
2021
- 2021-04-23 US US17/238,529 patent/US11919839B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2979391A1 (fr) | 2016-09-22 |
PH12017501669A1 (en) | 2018-03-19 |
US10508077B2 (en) | 2019-12-17 |
JP2018531213A (ja) | 2018-10-25 |
US20180044282A1 (en) | 2018-02-15 |
WO2016149099A1 (fr) | 2016-09-22 |
HK1249104A1 (zh) | 2018-10-26 |
KR20170124602A (ko) | 2017-11-10 |
US20160264518A1 (en) | 2016-09-15 |
US20220073452A1 (en) | 2022-03-10 |
SG11201707418WA (en) | 2017-10-30 |
ECSP17064695A (es) | 2017-10-31 |
US20200331847A1 (en) | 2020-10-22 |
US9745253B2 (en) | 2017-08-29 |
CA2979391C (fr) | 2023-10-17 |
US20190241506A1 (en) | 2019-08-08 |
CO2017009298A2 (es) | 2018-01-31 |
CN107531660A (zh) | 2018-01-02 |
US11919839B2 (en) | 2024-03-05 |
EP3932914A1 (fr) | 2022-01-05 |
CR20170420A (es) | 2017-10-03 |
BR112017019453A2 (pt) | 2018-05-15 |
US10988441B2 (en) | 2021-04-27 |
TW201639811A (zh) | 2016-11-16 |
US10266487B2 (en) | 2019-04-23 |
AU2016233568A1 (en) | 2017-10-05 |
PE20171517A1 (es) | 2017-10-20 |
IL254383A0 (en) | 2017-11-30 |
MX2017011778A (es) | 2017-12-04 |
US20180297939A1 (en) | 2018-10-18 |
EA201792028A1 (ru) | 2018-04-30 |
EP3268358A1 (fr) | 2018-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41677A (fr) | Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8 | |
MA45116A (fr) | Composés hétérocycliques comme immunomodulateurs | |
MA49858A (fr) | Composés, compositions et procédés | |
MA55064A (fr) | Composés utilisés comme inhibiteurs de kinase | |
MA43753A (fr) | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu | |
MA52119A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA50063A (fr) | Composés, compositions et procédés | |
DK3697376T3 (da) | Sammensætning | |
MA42923A (fr) | Composés bicycliques comme inhibiteurs mixtes de atx/ca | |
MA52546A (fr) | Compositions ciblées | |
DK3361870T3 (da) | Fungicidsammensætninger | |
ES2965669T3 (es) | Composición | |
MA41976A (fr) | Composition lubrifiante ultra-fluide | |
MA42597A (fr) | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
DK3334726T3 (da) | Plinabulinsammensætninger | |
MA41977A (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
FR3034100B1 (fr) | Composition lubrifiante | |
MA41803A (fr) | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques | |
DK3250182T3 (da) | Dispergible sammensætninger | |
KR20180084853A (ko) | 지혈 조성물 | |
DK3240767T3 (da) | Mikroindkapslede nitrifikationshæmmersammensætninger | |
DK3137437T3 (da) | Mikroindkapslet nitrifikationsinhibitorsammensætning | |
DK3331498T3 (da) | Nasalsammensætning | |
DK3717488T3 (da) | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer |